Rankings
▼
Calendar
TSHA FY 2024 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena
TSHA
Taysha Gene Therapies, Inc.
$1B
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
-46.1% YoY
Gross Profit
$8M
100.0% margin
Operating Income
-$91M
-1097.6% margin
Net Income
-$89M
-1071.6% margin
EPS (Diluted)
$-0.36
Cash Flow
Operating Cash Flow
-$81M
Free Cash Flow
-$82M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$160M
Total Liabilities
$89M
Stockholders' Equity
$72M
Cash & Equivalents
$139M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$15M
-46.1%
Gross Profit
$8M
$15M
-46.1%
Operating Income
-$91M
-$72M
-26.3%
Net Income
-$89M
-$112M
+20.0%
← Q4 2023
All Quarters
Q1 2024 →